Tryon Williams
Chairman at KIDOZ INC.
Net worth: 3 M $ as of 2024-06-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jason Williams | M | 49 | 23 years | |
| Eldad Tora | M | 54 | 11 years | |
| Henry Bromley | M | 53 | 22 years | |
| Fiona Curtis | F | 58 | 15 years | |
| Claes Kalborg | M | 62 | 6 years | |
| Moshe David | M | 59 | 5 years | |
| Lee Groat | M | - |
University of British Columbia
| 21 years |
| Neil Cashman | M | 72 |
University of British Columbia
| 19 years |
| Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 years |
| Michael Hitch | M | - |
University of British Columbia
| 17 years |
| Daniel Pauly | M | - |
University of British Columbia
| 30 years |
| Kevin McElwee | M | 54 |
University of British Columbia
| 20 years |
| R. Scott McKinley | M | 68 |
University of British Columbia
| 23 years |
| Steven Plotkin | M | - |
University of British Columbia
| 23 years |
| David M. Liu | M | 50 |
University of British Columbia
| 16 years |
| Tryon Williams | M | 53 | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nick Glover | M | 55 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
| Leonard Vernon | M | 80 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Ebba Dagmar Lucie Ljungerud | F | 52 | 4 years | |
| Helge Seetzen | M | - |
University of British Columbia
| 11 years |
| Paul Thomas | M | 50 |
University of British Columbia
| 3 years |
| Farzad Forooghian | M | 45 |
University of British Columbia
| 4 years |
| Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
| David Phillips | M | - |
University of British Columbia
| 4 years |
| Steve Veitch | M | - |
University of British Columbia
| 5 years |
| Ali Kashani | M | 39 |
University of British Columbia
| 3 years |
| Derek Hemmes | M | - |
University of British Columbia
| 10 years |
| Peeyush Varshney | M | 57 |
University of British Columbia
| 8 years |
| Vanessa Collette | F | - |
University of British Columbia
| 5 years |
| Johan Petter Erik Nylander | M | 60 | 1 years | |
| Akio Tanaka | M | 54 |
University of British Columbia
| 6 years |
| Mouane Sengsavang | F | 47 |
University of British Columbia
| 8 years |
| James Smith | M | 54 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 years |
| Jeff Hunter | M | - |
University of British Columbia
| 6 years |
| Li Zhu | F | - |
University of British Columbia
| 3 years |
| Wen Chuan Zhou | F | 40 |
University of British Columbia
| 5 years |
| Wale Bolorunduro | M | - |
University of British Columbia
| 4 years |
| Wen Wei Guan | M | 55 |
University of British Columbia
| 5 years |
| Kong Lok Yip | M | 48 |
University of British Columbia
| 5 years |
| Michael Leo | M | 47 |
University of British Columbia
| 6 years |
| Gabriel Fung | M | - |
University of British Columbia
| 7 years |
| Vladimir Cvijetinovic | M | - |
University of British Columbia
| 7 years |
| Hon Sum Sam Jor | M | 42 |
University of British Columbia
| 5 years |
| Frank S. Moyle | M | - |
University of British Columbia
| 9 years |
| Persio Pellegrini Rosario | M | - |
University of British Columbia
| 5 years |
| Ben De Wit | M | - |
University of British Columbia
| 7 years |
| Dong Xiao Qiu | M | 62 |
University of British Columbia
| 5 years |
| Salim Dhanji | M | 44 |
University of British Columbia
| 8 years |
| John Priatel | M | 58 |
University of British Columbia
| 11 years |
| Nick B. Drake | M | - |
University of British Columbia
| 10 years |
| Sebastian Jaimungal | M | - |
University of British Columbia
| 5 years |
| Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 years |
| Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
| George Whitton | M | 86 | - | |
| Amanda Gale Miller | F | 42 |
University of British Columbia
| 8 years |
| Jacqueline Simpson | F | - |
University of British Columbia
| 11 years |
| Robert E. Cohen | M | - |
University of British Columbia
| 11 years |
| Thomas Ian Alexander Allen | M | 83 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Roger Quick | M | - |
University of British Columbia
| 7 years |
| Henry Friesen | M | 90 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Hans Knapp | M | - |
University of British Columbia
| 3 years |
| Arsalan Farrokh | M | - |
University of British Columbia
| 4 years |
| Claire Huxtable | F | - |
University of British Columbia
| 6 years |
| Shaun Foy | M | - |
University of British Columbia
| 9 years |
| François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
| Trevor Robinson | M | - |
University of British Columbia
| 18 years |
| Christopher Mark Devereux | M | 59 | 16 years | |
| Mark Kowalski | M | 69 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
| Matthew Hamilton | M | 41 |
University of British Columbia
| 5 years |
| Arie Page | F | 45 |
University of British Columbia
| 8 years |
| Jonathan Bey | M | 54 |
University of British Columbia
| 5 years |
| Lei Huang | F | 41 |
University of British Columbia
| 4 years |
| Leonardo Viana Nicacio | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
| Michael Minor | M | - |
University of British Columbia
| 4 years |
| Jim Chan | M | - |
University of British Columbia
| 4 years |
| Asha Reeves | F | 52 |
University of British Columbia
| 4 years |
| Kristina Hess | F | - |
University of British Columbia
| 4 years |
| Rajeena Minhas | F | - |
University of British Columbia
| 4 years |
| Wendi V. Rodrigueza | M | 58 |
University of British Columbia
| 3 years |
| Adrian Crawford Ansell | M | 65 |
University of British Columbia
| 5 years |
| John Edward Veltheer | M | 58 |
University of British Columbia
| 3 years |
| Nousheen Huq | F | 53 |
University of British Columbia
| 3 years |
| Glans Graydon | M | 37 |
University of British Columbia
| 4 years |
| Keith Gillard | M | - |
University of British Columbia
| 5 years |
| Ryan Weymark | M | - |
University of British Columbia
| 4 years |
| Yao Yao | M | 35 |
University of British Columbia
| 4 years |
| Rory Edward North | M | - |
University of British Columbia
| 4 years |
| Ross Smith | M | 85 |
University of British Columbia
| 6 years |
| Brad Peters | M | 51 |
University of British Columbia
| 4 years |
| Michael Shaw | M | - |
University of British Columbia
| 4 years |
| Alvin Cheung | M | - |
University of British Columbia
| 5 years |
| Michael Leung | M | - |
University of British Columbia
| 4 years |
| Colin I. Godwin | M | 84 |
University of British Columbia
| 24 years |
| Chadwick Wasilenkoff | M | - |
University of British Columbia
| 4 years |
| Kevin Cohen | M | - |
University of British Columbia
| 3 years |
| Abdul Farooqi | M | - |
University of British Columbia
| 4 years |
| Wendy Louise Bach | F | 69 |
University of British Columbia
| 3 years |
| Randy Smallwood | M | 59 |
University of British Columbia
| 4 years |
| Jason Ng | M | - |
University of British Columbia
| 4 years |
| Paul McMillan | M | - |
University of British Columbia
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 89 | 89.00% |
| United Kingdom | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Tryon Williams
- Personal Network
